Trafalgar International (GCAN) Net Cash Flow Growth (3y) (2020 - 2026)
Trafalgar International (GCAN) Net Cash Flow Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.21 Bn | 39.55 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.48 Bn | 29.80 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.49 Bn | 15.10 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.70% |
| Dec 31, 2025 | -8.19% |
| Sep 30, 2025 | 37.65% |
| Jun 30, 2025 | 29.81% |
| Mar 31, 2025 | -3.95% |
| Dec 31, 2024 | 60.35% |
| Sep 30, 2024 | 37.13% |
| Jun 30, 2024 | -30.67% |
| Mar 31, 2024 | -29.75% |
| Dec 31, 2023 | 20.76% |
| Sep 30, 2023 | 6.17% |
| Jun 30, 2023 | 45.51% |
| Mar 31, 2023 | -27.41% |
| Dec 31, 2022 | 3.46% |
| Sep 30, 2022 | 14.36% |
| Jun 30, 2022 | 12.40% |
| Mar 31, 2022 | -27.95% |
| Dec 31, 2021 | -41.46% |
| Sep 30, 2021 | -28.98% |
| Jun 30, 2021 | 71.17% |